Security Snapshot

Zentalis Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (ZNTL) Institutional Ownership

CUSIP: 98943L107

13F Institutional Holders and Ownership History from Q2 2020 to Q3 2026

13F reference period

Q3 2026

Institutions Reporting

93

Shares (Excl. Options)

47.61MFull value: 47,610,829 · shares · 30 Sep 2026

Price

$2.77

The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0%
Share change
+8,563,890
Value change
+$22,718,788
Number of holders
93
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
97,315,887
SEC-reported price per share
$2.21
Insider filing price
$2.21
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • ZNTL - Zentalis Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share is tracked under CUSIP 98943L107.
  • 93 institutions reported positions in Q3 2026.
  • 9 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 115 to 93 between Q2 2026 and Q3 2026.
  • SEC-reported value moved from
    $229.58MFull value: $229,575,117 · USD · 30 Jun 2026
    to
    $131.74MFull value: $131,740,817 · USD · 30 Sep 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 93 institutions filings for Q3 2026.

Open SEC evidence

Security key

98943L107

13F reference period

Q3 2026

13F holders

93

13D/G owners

9

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
9
Security
ZNTL
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
WALTERS GROUP 19% -4.5% $77,268,733 +$18,770,550 17,844,973 +32% Walters William T 14 Aug 2026
Walters William T 9.9% +8.9% $10,081,500 +$786,500 7,050,000 +8.5% Walters William T 29 Jan 2025
Squadron Capital Management LLC 7.3% +44% $19,190,297 +$9,005,284 6,927,905 +88% Squadron Master Fund LP 30 Sep 2026
5AM Opportunities II (GP), LLC 5.3% -18% $11,398,610 +$705,368 5,157,742 +6.6% Kush Parmar 30 Sep 2026
BlackRock, Inc. 4.1% -22% $10,725,119 +$445,887 3,871,884 +4.3% BlackRock, Inc. 30 Sep 2026
VANGUARD GROUP INC 4.6% $4,677,873 3,271,240 The Vanguard Group 31 Dec 2024
BARCLAYS PLC 3.2% -43% $9,868,110 -$6,880,608 2,263,328 -41% Barclays PLC 30 Jun 2026
MILLENNIUM MANAGEMENT LLC 1.3% -80% $1,272,555 -$4,059,076 902,521 -76% Millennium Management LLC 30 Sep 2025
FMR LLC 0.2% $251,484 175,863 FMR LLC 29 Nov 2024
As of 30 Sep 2026, 93 institutional investors reported holding
47.61MFull value: 47,610,829 · shares · 30 Sep 2026
shares of Zentalis Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (ZNTL). This represents 49% of the company’s total
97.32MFull value: 97,315,887 · shares · Stored outstanding share count
outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
44%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Squadron Capital Management LLC 7% 6,827,905 5.6% $18,913,297
5AM Venture Management, LLC 4.1% 3,947,913 3.7% $10,935,719
NEA Management Company, LLC 3.7% 3,570,000 0.72% $9,888,900
VANGUARD CAPITAL MANAGEMENT LLC 3.6% 3,523,514 0% $9,760,134
TWO SIGMA INVESTMENTS, LP 2.9% 2,801,386 0.01% $7,759,839
Patient Square Capital LP 2.1% 2,007,485 0.89% $5,560,733
Seven Fleet Capital Management LP 1.5% 1,504,231 0.81% $4,166,720
RENAISSANCE TECHNOLOGIES LLC 1.5% 1,498,345 0.01% $4,150,416
Opaleye Management Inc. 1.5% 1,412,656 0.44% $3,913,057
Decheng Capital LLC 1.4% 1,323,327 0.54% $3,665,616
ORBIMED ADVISORS LLC 1.4% 1,315,355 0.07% $3,643,533
GEODE CAPITAL MANAGEMENT, LLC 1.3% 1,286,533 0% $3,564,696
VANGUARD PORTFOLIO MANAGEMENT LLC 1.3% 1,271,708 0% $3,522,631
Qube Research & Technologies Ltd 1.2% 1,135,037 0% $3,144,052
STATE STREET CORP 1.1% 1,110,357 0% $3,075,689
BANK OF AMERICA CORP /DE/ 1.1% 1,104,403 0% $3,059,197
Ishara Investments LP 1.1% 1,080,000 2.5% $2,991,600
Boxer Capital Management, LLC 1% 1,013,555 0.24% $2,807,547
PRIMECAP MANAGEMENT CO/CA/ 0.98% 957,420 0% $2,652,053
Pfizer Inc 0.98% 953,834 1.6% $2,575,352
Soleus Capital Management, L.P. 0.73% 706,280 0.07% $1,956,396
DIMENSIONAL FUND ADVISORS LP 0.73% 706,231 0% $1,955,637
Connor, Clark & Lunn Investment Management Ltd. 0.68% 664,857 0% $1,841,654
MARSHALL WACE, LLP 0.44% 426,889 0% $1,182,482
GSA CAPITAL PARTNERS LLP 0.42% 410,237 0.07% $1,136,000

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
26
Headline period
Q3 2026
Rows shown
1-25 of 26
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 47,610,829 $131,740,817 +$22,718,788 $2.77 93
2026 Q2 47,515,945 $229,575,117 +$26,028,250 $4.85 115
2026 Q1 43,560,789 $101,671,381 +$8,469,477 $2.34 100
2025 Q4 40,517,312 $54,747,323 -$20,028,376 $1.35 85
2025 Q3 52,751,330 $79,656,235 -$3,936,309 $1.51 96
2025 Q2 55,655,238 $64,573,024 -$4,209,380 $1.16 115
2025 Q1 58,450,755 $92,928,558 -$20,527,901 $1.59 131
2024 Q4 64,418,043 $195,184,400 -$24,736,255 $3.03 141
2024 Q3 70,964,067 $261,154,970 -$21,635,153 $3.68 133
2024 Q2 76,565,937 $313,165,477 -$54,359,485 $4.09 142
2024 Q1 85,290,558 $1,344,227,610 +$67,005,140 $15.76 140
2023 Q4 81,068,438 $1,228,198,230 -$21,970,408 $15.15 118
2023 Q3 80,197,042 $1,608,751,464 -$51,643,382 $20.06 136
2023 Q2 82,228,758 $2,319,672,532 +$442,954,370 $28.21 131
2023 Q1 67,021,594 $1,152,767,927 +$44,945,526 $17.20 108
2022 Q4 64,360,813 $1,296,145,033 +$105,231,060 $20.14 106
2022 Q3 58,811,479 $1,273,846,102 -$54,003,564 $21.66 116
2022 Q2 58,254,677 $1,636,896,016 +$359,446,058 $28.10 115
2022 Q1 44,437,538 $2,050,628,439 +$49,057,461 $46.14 123
2021 Q4 42,987,158 $3,611,907,936 +$90,022,119 $84.06 134
2021 Q3 41,250,292 $2,749,252,645 +$115,288,600 $66.64 114
2021 Q2 39,699,603 $2,112,018,735 +$205,833,024 $53.20 117
2021 Q1 36,327,192 $1,576,156,109 -$55,960,381 $43.39 93
2020 Q4 37,299,066 $1,937,340,198 +$309,645,949 $51.94 104
2020 Q3 31,635,340 $1,033,195,545 +$169,604,096 $32.69 65
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .